Journal of Clinical Oncology Impact Factor 41.9: Publishing Guide

JCO is where practice-changing trials go, not interesting biology

If your paper's main contribution is understanding cancer biology, consider Cancer Cell or Nature Cancer. JCO is for changing how patients get treated, not advancing mechanistic understanding.

The ASCO connection matters enormously

JCO papers often get featured at ASCO conferences, which amplifies impact. Timing your submission around ASCO abstract deadlines can be strategic for maximum visibility.

Negative trials are genuinely valued if well-designed

Definitive evidence that a treatment doesn't work changes practice too. JCO publishes high-quality negative trials that prevent adoption of ineffective therapies.

The editorial process includes practicing oncologists

JCO reviewers are clinicians who see patients. They ask different questions than academic researchers: 'Would I give this to my patients? How do I explain this to families?'

Patient advocacy input is increasingly valued

JCO considers patient perspectives in editorial decisions. If patient advocates were involved in your trial design or interpretation, highlight this prominently.

Health economics and outcomes research have a real place

Cost-effectiveness analyses, health services research, and implementation studies that affect how cancer care is delivered find a home at JCO alongside clinical trials.

The rapid communication track exists for urgent findings

For safety signals or practice-changing results that can't wait for normal review timelines, JCO offers expedited review and publication.

International collaborations strengthen submissions

Multi-country trials that demonstrate global applicability perform better than single-country studies. Cancer is a global disease requiring global solutions.